Has use of PSMA PETCT revealed increased local failures than previously known after definitive prostate EBRT with biochemical failure?

Answer from: Radiation Oncologist at Academic Institution

Prior to the advent of PET imaging, the published rates of local recurrence (LR) after definitive RT vary widely in phase III trials from ≈ 1% (e.g., PCS IV) to ≈ 30% (e.g., PROG 9509). The heterogeneity is likely explained by several factors including (1) differences in baseline risk of...

Comments

Radiation Oncologist at Toledo Clinic Inc.
Great summary. What is the data for salvage with b...

Radiation Oncologist at National Institutes of Health Clinical Center
It is clear to me that the toxicity of a salvage p...

Medical Oncologist at UPMC Hillman Cancer Center
Great summary. FYI have you used Posluma (flotufol...

Radiation Oncologist at National Institutes of Health Clinical Center
We have not used 18F-rhPSMA-7.3 (flotufolastat) he...

Answer from: Radiation Oncologist at Academic Institution

Yes

Comments

Radiation Oncologist at Rush Medical College of Rush University
Agree

Answer from: Radiation Oncologist at Community Practice

Anecdotally, with > 300 institutional PSMA scans, yes. MpMRI is still good for prostate since renal excretion of PET tracer limits sensitivity.

Please select the option that best describes you:

Has use of PSMA PETCT revealed increased local failures than previously known after definitive prostate EBRT with biochemical failure?

Related Questions